Kidney injury occuring in liver failure is a historical scenario imbued w/in the parlance of medicine for centuries. In this article, I try to discuss HRS— its current concepts & challenges.
Thank you @Nephro_Sparks@DearbhlaKelly4 for helping me write this article!
Hypertension control remains stubbornly low in underserved communities. IMPACTS‑BP asks whether a team‑based, multi‑component approach can meaningfully improve blood pressure control and adherence in low‑income patients
🎨#VisualAbstract by @DrAkshayaJnephjc.com/news/2026/5/18/im…
1/10
#NephJC#TenPostNephJC.
#NephTwitter
In 2026 💊 FDA approved sparsentan for FSGS, an endothelin A/angiotensin II receptor inhibitor.
Next up in the pipeline…transient receptor potential cation channel 6 (TRPC6) inhibitor (BI 764198) 🚰
Article 👇
pubmed.ncbi.nlm.nih.gov/4161…
Blessings abound! The Division received various awards during the recent convention:
1. One of the Most Outstanding Fellowship Training Institution in Adult Nephrology
2. 100% passing recent Board exams
3. One of the Best performing institution in test construction
#TatakPGH
Hydralazine, a 1950s drug still used at the edges of modern care
Cheap. Available.
Signal of benefit… shadowed by decades of immune toxicity signals
58 min to #TenPostNephJC#NephJCpubmed.ncbi.nlm.nih.gov/6786…
Managing glomerular disease in tropical regions require a specialized lens. Join #GlomConPH on April 22, 2026, for a high-impact workshop designed for physicians to master the nuances of tropical nephrology—from biopsy interpretation to navigating the latest KDIGO updates.
0/10
Hey NephJC faithful, we are shaking it up.
Given the 📉 attendance at live chats we’re changing to a summary 🧵& ❓ to answer, at your convenience.
Still tag us #NephJC to get the discussion going!
PS If we hear enough comments, we might bring chats back!😉
The IgAN Nephropathy curriculum provides a comprehensive review of the pathogenesis, treatment, and prediction of disease progression to help clinicians in their work.
Access the new curriculum, supported by Otsuka: bit.ly/3PirS4N
#ISNWCN second HIT1 trial
Semaglutide Improves Kidney Outcomes Regardless Of SGLT2i Use In People With Chronic Kidney Disease And Type 2 Diabetes: Post-hoc Analysis The Remodel Trial, by David Cherney
#ISNWCN
First simultaneous publication comes from Hiddo Heerspink and ASSIST trial ✨
Phase II randomized crossover in IgAN on RASi SGLT2i. Atrasentan 0.75 mg reduced 24-h UPCR vs placebo. ETA blockade adds antiproteinuric effect on top of optimized therapy
2/ @brian_rifkin 's recap highlighted our progress and future plans, but what stays with me is this: #nephjc never stops adapting. We keep learning, improving, and reaching for a better version of ourselves 🌟
Delighted that FIND CKD has meet its primary endpoint. Fantastic news for patients with non-diabetic CKD, including those with GNs, including IgAN
Thank you to Bayer, all the investigators, study teams & patients who have made FIND-CKD possible
bayer.com/media/en-us/finere…
Proactive vs Reactive DDAVP: The Clamp Finally Faces an RCT
Thank you Thai Air Force for doing the trials that need to be done!
pbfluids.com/2026/03/proacti…
New terminology for iron deficiency in CKD ca. 2026 from @goKDIGO#Nephpearls
Systemic iron deficiency
(previously Absolute iron deficiency)
⬇️ Ferritin ⬇️ TSAT
Iron-restricted erythropoiesis
(previously Functional iron deficiency)
⬆️ Ferritin ⬇️ TSAT
👉 kdigo.org/guidelines/anemia-…